We are pleased to be recommended again in the latest…
Elisabeth Greiner
Partner
Dr. rer. nat. Mag. pharm.
Dr. Greiner joined df-mp in 2005 and is a member of the firm’s chemistry and pharmaceuticals practice groups. She is a partner in the firm since 2012 and has an in-depth scientific background in the area of pharmaceutical sciences, in particular in organic and medicinal chemistry, drug formulation and pharmacology.
Dr. Greiner is authorized to represent clients before the German Patent and Trademark Office, the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.
+ 49 89 210 296 0
elisabeth.greiner@df-mp.com
Dr. Greiner joined df-mp in 2005 and is a member of the firm’s chemistry and pharmaceuticals practice groups. She is a partner in the firm since 2012 and has an in-depth scientific background in the area of pharmaceutical sciences, in particular in organic and medicinal chemistry, drug formulation and pharmacology.
Dr. Greiner is authorized to represent clients before the German Patent and Trademark Office, the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.
practice areas.
Dr. Greiner’s practice focuses on prosecution, opposition and litigation matters concerning German and European patents. She has been involved in various multi-national patent disputes regarding patents in the above areas of technology. A further focus of Dr. Greiner’s work lies in rendering patent validity and infringement opinions in connection with freedom-to-operate und due diligence projects, as well as counselling clients in matters relating to supplementary protection certificates (SPCs) for pharmaceuticals in Europe.
We are delighted to be listed again in this year's…
df-mp joins the ranks of "highly recommended" patent law firms…
We proudly announce that df-mp is among the most recommended patent…
Sucess for Ceva: The company is now allowed to market its…
df-mp is proud to receive another five IP stars this…
The pharmaceutical companies Hexal and Teva may continue to sell…
The patent disputes of our client Hexal AG over the…
df-mp is delighted that five partners have been awarded the…
df-mp is recommended in the current JUVE-Handbook with the highest…
admissions.
- German Patent Attorney
- European Patent Attorney
- European Trademark Attorney
- European Design Attorney
references and activities.
- Author and co-author of numerous scientific publications in the field of organic and medicinal chemistry
- Organizer of IP-workshops
- Lecturer of IP-seminars at the MCI (Management Center Innsbruck, the entrepreneurial school, Austria)
curriculum vitae.
Since 2012
Partner at df-mp
Since 2008
Patent attorney at df-mp
2005-2008
Legal trainee at df-mp, the German Patent and Trademark Office (DPMA) and the German Federal Patent Court (BPatG)
2001-2005
Postdoctoral research fellow in the Laboratory of Medicinal Chemistry at the National Institute of Health (NIH) in Bethesda, MD, U.S.A.
1999-2000
Doctorate Degree (with honors) in Medicinal Chemistry from University of Innsbruck, Institute of Pharmacy, Austria
1996
Degree (Mag.pharm. with honors) in Medicinal Chemistry from University of Innsbruck, Institute of Pharmacy, Austria
Representative cases.
- Glatirameracetat / Copaxone®: infringement proceedings, utility model cancellation proceedings
- Fulvestrant / Faslodex®: Formulation patents, nullity proceedings (BGH X ZR 59/17), opposition proceedings, various infringement proceedings
- Fulvestrant / Faslodex®: Patent of use, infringement proceedings
- Calcipotriol – Betamethason / Calcipotriol comp Hexal®: several opposition proceedings, infringement proceedings
- DMF / Tecfidera®: various opposition procedures
- Anti-VEGF Antibody / Avastin® Xeloda®: opposition procedures
association memberships.
publications.
- Greiner, E.; Schottenberger, H.; Wurst, K.; Schmidhammer, H.: Novel Class of Morphinans with Acrylonitrile Incorporated Substructures as Key Intermediates for non-Oxygen-Bridged Opioid Ligands. J. Am. Chem. Soc. 2001, 123, 3840-3841.
- Greiner, E.; Atkinson, A.J.J.; Ayala, A.; Chrousos, G.P.; Contoreggi, C.; Eckelman, W.C.; Gold, P.W.; Habib, K.E.; Jacobson, A.E.; Webster, E.L.; Rice K.C.: Synthesis of Doubly 13C-Labelled Antalarmin Isotopomers for Pharmacokinetic Studies. J. Labelled Cpd. Radiopharm. 2002, 45, 637-645.
- Greiner, E.; Prisinzano, T.; Johnson II, E.M.; Dersch, C.M.; Marcus, J.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. J. Med. Chem. 2003, 46, 1465-1469.
- Greiner, E.; Spetea, M.; Krassnig, R.; Schuellner, F.; Aceto, M.; Harris, L.S.; Traynor, J.R.; Woods, J.H.; Winger, G.; Coop, A.; Schmidhammer, H.: Synthesis and Biological Evaluation of 14-Alkoxymorphinans – Part 18 – N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships. J. Med. Chem. 2003, 46, 1758-1763.
- Jagoda, E.; Contoreggi, C.; Lee, M.; Kao, C.K.; Szajak, L.P.; Listwak, S.; Gold, P.W.; Chrousos, G.P.; Greiner, E.; Kim B.M., Jacobson, A.E.; Rice K.C.: Eckelman, W.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: Synthesis of [Br-76]MJL-1-109-2. J. Med. Chem. 2003, 46, 3559-3562.
- Greiner, E.; Folk, J.E.; Jacobson, A.E.; Rice, K.C.: A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg. Med. Chem. 2004, 12, 223-238.
- Seggewiss, R.; Lore, K.; Greiner E.; Magnusson M.K.; Price D.A.; Douek D.C.; Dunbar C.E.; Wiestner A.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 15, 2473-2479.
- Greiner, E.; Boos, T.L.; Prisinzano T.E.; De Martino, M.G.; Zeglis, B.; Dersch, C.M.; Marcus, J.; Partilla, J.S.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Design and Synthesis of Promiscuous High Affinity Monoamine Transporter Ligands: An Attempt at Unraveling Transporter Selectivity. J. Med. Chem. 2006 Mar 9;49(5):1766-72.
- Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008 Apr 15;14(8):2484-91.
